SGLT-2 Therapy Center

While it does not yet have FDA approval, researchers find novel dual SGLT-1/2 inhibitor, sotagliflozin, is efficacious and safe for patients with type 2 diabetes.

CREDENCE trial shows that canagliflozin, an SGLT2 inhibitor, lowers the risk of cardiovascular and renal events in patients with T2DM, regardless of prior history of heart failure. 

Canagliflozin, an SGLT2 inhibitor, and its impact in reducing hospitalizations and health care costs in people with type 2 diabetes.

Are the mortality and cardiovascular benefits of SGLT-2 inhibitors limited to patients with type 2 diabetes who have established cardiovascular disease and renal disease?

The FDA has approved empagliflozin Breakthrough therapy for patients with heart failure with preserved ejection fraction (HFpEF).

Patients had significant reduction in urinary albumin-to-creatinine ratio (UACR) in the first six months of using dapagliflozin.

The most common treatment for T2D has been the metformin-sulfonylurea combo; how do SGLT-2 inhibitors compare in all-cause mortality risk?

Researchers compare the cardiovascular effectiveness and safety of GLP-1 agonists and SGLT-2 inhibitors in older adults.

Can a new potential treatment combining an SGLT-2 and a GLP-1 RA mitigate cardiometabolic risk?

A VERTIS CV sub study showed significant improvements in glycemic control after adding ertugliflozin to insulin-based regimens.